Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Chemotherapy. Hormone. Stanford University, Stanford, CA, United States



Survival: 22.0 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
Hormone
   
Drugs:
Country: United States
   
City/State/Province: Stanford, CA
   
Hospital: Stanford University
   
Journal: Link
   
Date: 7/2013

Description:
Patients:
This study involved 39 peripheral T-cell lymphoma (PTCL) and natural killer (NK) cell lymphoma patients with a median age of 60 years; 72% were male.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab and the chemotherapy regimen known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).

Toxicities:
There was one death during the study due to heart failure that may have been due to treatment. Treatment-related grade 2-4 heart problems were reported in six patients. Grade 4 neutropenia was also reported.

Results:
The median overall survival was 22 months.

Support:
One of the authors is employed by Genentech, makers of bevacizumab.

Correspondence: Dr. Kristen N. Ganjoo; email: kganjoo@stanford.edu

E-mail to a Friend Email Physician More Information